Build the operating model. Generate the evidence. Earn the right to scale.
PRISMqd is an early-stage clinical-safety operating architecture focused on how decision-critical signals move from recognition through escalation, action, reassessment, and validated closure.
The company is raising $2 million to convert existing frameworks, product specifications, and prototypes into a controlled enterprise design-partnership program, evidence-generation capability, and validated product roadmap.
Request investor materialsWhat exists today
- Founder-owned clinical-safety architecture and product portfolio
- Published frameworks with persistent public records
- Defined rescue-readiness implementation pathway
- Working browser prototypes and inspectable interaction models
- U.S. provisional patent application filed for the PRISMqd architecture
- Founder with more than 20 years of healthcare experience
What has not been established
- Product-market fit
- Clinical or operational effectiveness
- Repeatable enterprise adoption
- Revenue or economic return
- Regulatory classification or clearance for future software capabilities
Evidence-led product development.
Enterprise
Design-partnership development and delivery.
Evidence and governance
Clinical, regulatory, privacy, security, and human-factors review.
Product
Canonical product finalization and technical work tied to validated workflows.
Clinical-safety failure can be a continuity problem.
PRISMqd’s thesis is that decision-critical information can lose meaning, authority, ownership, or closure as it moves through a complex organization.
The company is testing whether a shared operating architecture can help hospitals examine and improve that sequence. The near-term commercial vehicle is a bounded paid design partnership. Broader licensing and software delivery are contingent on evidence.
PRISMqd is early stage. Product, clinical, regulatory, security, reimbursement, adoption, and economic assumptions remain subject to testing. Projections, if provided in diligence materials, are scenarios rather than guarantees.
Request the appropriate diligence materials.
Use professional contact information. Do not include patient information, confidential diligence material, or sensitive institutional data in ordinary email.
Request investor materials